Please use this identifier to cite or link to this item:
https://dspace.uzhnu.edu.ua/jspui/handle/lib/44545
Full metadata record
DC Field | Value | Language |
---|---|---|
dc.contributor.author | Wolinsky, Jerry S. | - |
dc.contributor.author | Narayana, Ponnada A. | - |
dc.contributor.author | Nelson, Flavia | - |
dc.contributor.author | Datta, Sushmita | - |
dc.contributor.author | O’Connor3, Paul | - |
dc.contributor.author | Confavreux, Christian | - |
dc.contributor.author | Comi, Giancarlo | - |
dc.contributor.author | Kappos, Ludwig | - |
dc.contributor.author | Olsson, Tomas P. | - |
dc.contributor.author | Truffinet, Philippe | - |
dc.contributor.author | Wang, Lin | - |
dc.contributor.author | Miller, Aaron | - |
dc.contributor.author | Freedman, Mark S. | - |
dc.contributor.author | Teriflunomide Multiple Sclerosis Oral (TEMSO) Trial Group | - |
dc.date.accessioned | 2022-09-28T09:54:53Z | - |
dc.date.available | 2022-09-28T09:54:53Z | - |
dc.date.issued | 2013 | - |
dc.identifier.citation | Wolinsky J.S end ochers Magnetic resonance imaging outcomes from a phase III trial of teriflunomide / J. S. Wolinsky, P. A. Narayana., F. Nelson, et al. // Multiple Sclerosis Journal. - SACE, 2013. Vol. 19(10). – P. 1310-1319. | uk |
dc.identifier.uri | https://dspace.uzhnu.edu.ua/jspui/handle/lib/44545 | - |
dc.description.abstract | Objective: The purpose of this study was to determine the effects of oral teriflunomide on multiple sclerosis (MS) pathology inferred by magnetic resonance imaging (MRI). Methods: Patients (n=1088) with relapsing MS were randomized to once-daily teriflunomide 7 mg or 14 mg, or placebo, for 108 weeks. MRI was recorded at baseline, 24, 48, 72 and 108 weeks. Annualized relapse rate and confirmed progression of disability (sustained ≥12 weeks) were the primary and key secondary outcomes. The principal MRI outcome was change in total lesion volume. Results: After 108 weeks, increase in total lesion volume was 67.4% (p=0.0003) and 39.4% (p=0.0317) lower in the 14 and 7 mg dose groups versus placebo. Other measures favoring teriflunomide were accumulated enhanced lesions, combined unique activity, T2-hyperintense and T1-hypointense component lesion volumes, white matter volume, and a composite MRI score; all were significant for teriflunomide 14 mg and most significant for 7 mg versus placebo. Conclusions: Teriflunomide provided benefits on brain MRI activity across multiple measures, with a dose effect evident on several markers. These effects were also consistent across selected subgroups of the study population. These findings complement clinical data showing significant teriflunomide-related reductions in relapse rate and disease progression, and demonstrate containment of MRI-defined disease progression. | uk |
dc.language.iso | en | uk |
dc.publisher | SACE | uk |
dc.subject | teriflunomide | uk |
dc.subject | multiple sclerosis | uk |
dc.subject | disease-modifying therapy | uk |
dc.subject | magnetic resonance imaging | uk |
dc.subject | phase III | uk |
dc.subject | clinical tria | uk |
dc.title | Magnetic resonance imaging outcomes from a phase III trial of teriflunomide | uk |
dc.type | Text | uk |
dc.pubType | Стаття | uk |
Appears in Collections: | Наукові публікації кафедри неврології, нейрохірургії та психіатрії |
Files in This Item:
File | Description | Size | Format | |
---|---|---|---|---|
Magnetic.pdf | 389.25 kB | Adobe PDF | View/Open |
Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.